212 related articles for article (PubMed ID: 20215039)
21. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
Zwahlen DR; Smith R; Andrianopoulos N; Matheson B; Royce P; Millar JL
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):179-87. PubMed ID: 20378267
[TBL] [Abstract][Full Text] [Related]
23. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
24. The impact of perineural invasion on biochemical outcome after permanent prostate iodine-125 brachytherapy.
Piña AG; Crook JM; Kwan P; Borg J; Ma C
Brachytherapy; 2010; 9(3):213-8. PubMed ID: 20022565
[TBL] [Abstract][Full Text] [Related]
25. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
26. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
McMullen KP; deGuzman AF; McCullough DL; Lee WR
Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
[TBL] [Abstract][Full Text] [Related]
27. Perineal prostatic cancer seeding following radioactive seed brachytherapy.
Teh BS; Chou CC; Schwartz MR; Mai WY; Carpenter LS; Butler EB
J Urol; 2001 Jul; 166(1):212. PubMed ID: 11435863
[No Abstract] [Full Text] [Related]
28. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
29. [Value of positive resection margins in patients with pT2 prostate cancer. Implications for adjuvant treatment].
Rosas-Nava JE; Herranz-Amo F; Paños-Fagundo EV; Lledó-García E; Verdú-Tartajo F; Hernández-Fernández C
Actas Urol Esp; 2011 May; 35(5):272-6. PubMed ID: 21397985
[TBL] [Abstract][Full Text] [Related]
30. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
31. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
32. Editorial comment.
Lee WR
Urology; 2010 Jun; 75(6):1416-7; author reply 1417. PubMed ID: 20513503
[No Abstract] [Full Text] [Related]
33. [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
Guinot JL; Ricós JV; Gimeno J; Tortajada MI; Carrascosa M; Santos M; Casanova J; Soler P; Crispín V; Arribas L
Actas Urol Esp; 2011 Jun; 35(6):339-44. PubMed ID: 21481974
[TBL] [Abstract][Full Text] [Related]
34. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
35. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
[TBL] [Abstract][Full Text] [Related]
36. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
[TBL] [Abstract][Full Text] [Related]
37. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
Galego P; Silva FC; Pinheiro LC
Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
[TBL] [Abstract][Full Text] [Related]
38. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters.
Butler WM; Stewart RR; Merrick GS
Brachytherapy; 2011; 10(1):16-28. PubMed ID: 20149981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]